- The viscosupplementation market is steadily growing as more individuals seek effective non-surgical options to manage joint pain and maintain mobility. This trend reflects a shift toward treatment approaches that offer relief with fewer side effects and quicker recovery times compared to traditional methods
- Healthcare providers are increasingly recommending viscosupplementation treatments to patients with moderate osteoarthritis symptoms who wish to delay or avoid surgery. The market is seeing continued investment in product innovation and procedural advancements to meet the evolving needs of both patients and clinicians
- North America is expected to dominate the viscosupplementation market due to its advanced healthcare infrastructure, high adoption rate of innovative treatments, and the growing prevalence of osteoarthritis in the aging population.
- Asia-Pacific is expected to be the fastest growing region in the viscosupplementation market during the forecast period due to a rapidly aging population, improving healthcare access, and increasing awareness of joint health treatments in emerging economies such as China and India.
- The three-injection regimen segment is expected to dominate the viscosupplementation market with the largest share of 48.9% in 2025 due to its established clinical efficacy, long-standing usage by healthcare professionals, and ability to provide sustained pain relief in moderate osteoarthritis cases.
